Structural analysis of light chain-driven bispecific antibodies targeting CD47 and PD-L1

References

• Mullard A. FDA approves 100th monoclonal antibody product. Nat Rev Drug Discov. 2021;20(7):491–14. doi:10.1038/d41573-021-00079-7.
   PubMed Web of Science ®Google Scholar
• Kaplon H, Crescioli S, Chenoweth A, Visweswaraiah J, Reichert JM. Antibodies to watch in 2023. Mabs-austin. 2023;15(1):2153410. doi:10.1080/19420862.2022.2153410.
   PubMed Web of Science ®Google Scholar
• Antibody therapeutics approved or in regulatory review in the EU or US. The antibody society. https://www.antibodysociety.org/resources/approved-antibodies/.
   Google Scholar
• Berman HM, Westbrook J, Feng Z, Gilliland G, Bhat TN, Weissig H, Shindyalov IN, Bourne PE. The protein data bank. Nucleic Acids Res. 2000;28(1):235–42. doi:10.1093/nar/28.1.235.
   PubMed Web of Science ®Google Scholar
• Kunik V, Peters B, Ofran Y, Baker B. Structural consensus among antibodies defines the antigen binding site. PLOS Comput Biol. 2012;8(2):e1002388. doi:10.1371/journal.pcbi.1002388.
   PubMed Web of Science ®Google Scholar
• Reis PBPS, Barletta GP, Gagliardi L, Fortuna S, Soler MA, Rocchia W. Antibody-antigen binding interface analysis in the big data era. Front Mol Biosci. 2022;9. doi:10.3389/fmolb.2022.945808.
   Web of Science ®Google Scholar
• Luo S, Su Y, Peng X, Wang S, Peng J, Ma J. Antigen-specific antibody design and optimization with diffusion-based generative models for protein structures. 2022; doi:10.1101/2022.07.10.499510.
   Google Scholar
• Xu JL, Davis MM. Diversity in the CDR3 region of VH is sufficient for most antibody specificities. Immunity. 2000;13(1):37–45. doi:10.1016/S1074-7613(00)00006-6.
   PubMed Web of Science ®Google Scholar
• Tsuchiya Y, Mizuguchi K. The diversity of H 3 loops determines the antigen-binding tendencies of antibody CDR loops. Protein Sci. 2016;25(4):815–25. doi:10.1002/pro.2874.
   PubMed Web of Science ®Google Scholar
• Barrios Y, Jirholt P, Ohlin M. Length of the antibody heavy chain complementarity determining region 3 as a specificity-determining factor. J Mol Recognit. 2004;17(4):332–38. doi:10.1002/jmr.679.
   PubMed Web of Science ®Google Scholar
• Ippolito GC, Schelonka RL, Zemlin M, Ivanov II, Kobayashi R, Zemlin C, Gartland GL, Nitschke L, Pelkonen J, Fujihashi K, et al. Forced usage of positively charged amino acids in immunoglobulin CDR-H3 impairs B cell development and antibody production. J Exp Med. 2006;203(6):1567–78. doi:10.1084/jem.20052217.
   PubMed Web of Science ®Google Scholar
• Cobb RM, Oestreich KJ, Osipovich OA, Oltz EM. Accessibility control of V(D)J recombination. Adv Immunol. 2006;91:45–109.
   PubMed Web of Science ®Google Scholar
• Bassing CH, Swat W, Alt FW. The mechanism and regulation of chromosomal V(D)J recombination. Cell. 2002;109(2):S45–55. doi:10.1016/S0092-8674(02)00675-X.
   PubMedGoogle Scholar
• Ridgway JB, Presta LG, Carter P. ‘Knobs-into-holes’ engineering of antibody CH3 domains for heavy chain heterodimerization. Protein Eng Des Sel. 1996;9(7):617–21. doi:10.1093/protein/9.7.617.
   Google Scholar
• Klein C, Schaefer W, Regula JT. The use of CrossMAb technology for the generation of bi- and multispecific antibodies. Mabs-austin. 2016;8(6):1010–20. doi:10.1080/19420862.2016.1197457.
   PubMed Web of Science ®Google Scholar
• Sandeep Shinde SH, Shinde SH, Pande AH. Polyspecificity - an emerging trend in the development of clinical antibodies. Mol Immunol. 2023;155:175–83. doi:10.1016/j.molimm.2023.02.005.
   PubMed Web of Science ®Google Scholar
• Labrijn AF, Janmaat ML, Reichert JM, Parren PWHI. Bispecific antibodies: a mechanistic review of the pipeline. Nat Rev Drug Discov. 2019;18(8):585–608. doi:10.1038/s41573-019-0028-1.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. Bispecific antibodies. Science. 2021;372(6545):916–17. doi:10.1126/science.abg1209.
   PubMed Web of Science ®Google Scholar
• Brinkmann U, Kontermann RE. The making of bispecific antibodies. Mabs-austin. 2017;9(2):182–212. doi:10.1080/19420862.2016.1268307.
   PubMed Web of Science ®Google Scholar
• Kontermann RE. Dual targeting strategies with bispecific antibodies. Mabs-austin. 2012;4(2):182–97. doi:10.4161/mabs.4.2.19000.
   PubMed Web of Science ®Google Scholar
• Fischer N, Elson G, Magistrelli G, Dheilly E, Fouque N, Laurendon A, Gueneau F, Ravn U, Depoisier J-F, Moine V, et al. Exploiting light chains for the scalable generation and platform purification of native human bispecific IgG. Nat Commun. 2015;6(1):6113. doi:10.1038/ncomms7113.
   PubMedGoogle Scholar
• Dheilly E, Moine V, Broyer L, Salgado-Pires S, Johnson Z, Papaioannou A, Cons L, Calloud S, Majocchi S, Nelson R, et al. Selective blockade of the ubiquitous checkpoint receptor CD47 is enabled by dual-targeting bispecific antibodies. Mol Ther. 2017;25(2):523–33. doi:10.1016/j.ymthe.2016.11.006.
   PubMed Web of Science ®Google Scholar
• Ferlin W, Masternak K, Shang L. Selective CD47 targeting with a bispecific antibody. Cancer Immunol Immunother. 2021;70(4):1161–62. doi:10.1007/s00262-020-02812-4.
   PubMed Web of Science ®Google Scholar
• Buatois V, Johnson Z, Salgado-Pires S, Papaioannou A, Hatterer E, Chauchet X, Richard F, Barba L, Daubeuf B, Cons L, et al. Preclinical development of a bispecific antibody that safely and effectively targets CD19 and CD47 for the treatment of B cell lymphoma and leukemia. Mol Cancer Ther. 2018;17(8):1739–51. doi:10.1158/1535-7163.MCT-17-1095.
   PubMed Web of Science ®Google Scholar
• Hatterer E, Chauchet X, Richard F, Barba L, Moine V, Chatel L, Broyer L, Pontini G, Bautzova T, Juan F, et al. Targeting a membrane-proximal epitope on mesothelin increases the tumoricidal activity of a bispecific antibody blocking CD47 on mesothelin-positive tumors. Mabs-austin. 2020;12(1):1739408. doi:10.1080/19420862.2020.1739408.
   PubMed Web of Science ®Google Scholar
• Chauchet X, Cons L, Chatel L, Daubeuf B, Didelot G, Moine V, Chollet D, Malinge P, Pontini G, Masternak K, et al. CD47xCD19 bispecific antibody triggers recruitment and activation of innate immune effector cells in a B-cell lymphoma xenograft model. Exp Hematol Oncol. 2022;11(1):26. doi:10.1186/s40164-022-00279-w.
   PubMed Web of Science ®Google Scholar
• Gueneau F, Ravn U, Fischer N. Round optimization for improved discovery of native bispecific antibodies. Methods. 2019;154:51–59. doi:10.1016/j.ymeth.2018.11.009.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Majocchi S, Moine V, Nouveau L, Ngoc H, Daubeuf B, Ravn U, Pleche N, Calloud S, Broyer L, et al. Development and characterization of NILK-2301, a novel CEACAM5xCD3 κλ bispecific antibody for immunotherapy of CEACAM5-expressing cancers. J Hematol Oncol. 2023;16(1):117. doi:10.1186/s13045-023-01516-3.
   PubMed Web of Science ®Google Scholar
• Seckinger A, Buatois V, Moine V, Daubeuf B, Richard F, Chatel L, Viandier A, Bosson N, Rousset E, Masternak K, et al. Targeting CEACAM5-positive solid tumors using NILK-2401, a novel CEACAM5xCD47 κλ bispecific antibody. Front Immunol. 2024;15:1378813. doi:10.3389/fimmu.2024.1378813.
   PubMed Web of Science ®Google Scholar
• Lefranc MP, Giudicelli V, Ginestoux C, Bodmer J, Muller W, Bontrop R, Lemaitre M, Malik A, Barbie V, Chaume D, et al. IMGT, the international ImMunoGeneTics database. Nucleic Acids Res. 1999;27(1):209–12. doi:10.1093/nar/27.1.209.
   PubMed Web of Science ®Google Scholar
• Maute RL, Gordon SR, Mayer AT, McCracken MN, Natarajan A, Ring NG, Kimura R, Tsai JM, Manglik A, Kruse AC, et al. Engineering high-affinity PD-1 variants for optimized immunotherapy and immuno-PET imaging. Proc Natl Acad Sci USA. 2015;112(47):E6506–14. doi:10.1073/pnas.1519623112.
   PubMed Web of Science ®Google Scholar
• Pietsch EC, Dong J, Cardoso R, Zhang X, Chin D, Hawkins R, Dinh T, Zhou M, Strake B, Feng P-H, et al. Anti-leukemic activity and tolerability of anti-human CD47 monoclonal antibodies. Blood Cancer J. 2017;7(2):e536–536. doi:10.1038/bcj.2017.7.
   PubMed Web of Science ®Google Scholar
• Zak KM, Kitel R, Przetocka S, Golik P, Guzik K, Musielak B, Dömling A, Dubin G, Holak TA. Structure of the complex of human programmed death 1, PD-1, and its ligand PD-L1. Structure. 2015;23(12):2341–48. doi:10.1016/j.str.2015.09.010.
   PubMed Web of Science ®Google Scholar
• Sparta KM, Krug M, Heinemann U, Mueller U, Weiss MS. Xdsapp2.0. J Appl Crystallogr. 2016;49(3):1085–92. doi:10.1107/S1600576716004416.
   Google Scholar
• Kabsch W. Xds. Acta Crystallogr D Biol Crystallogr. 2010;66(2):125–32. doi:10.1107/S0907444909047337.
   PubMedGoogle Scholar
• Evans P. Scaling and assessment of data quality. Acta Crystallogr D Biol Crystallogr. 2006;62(1):72–82. doi:10.1107/S0907444905036693.
   PubMedGoogle Scholar
• McCoy AJ, Grosse-Kunstleve RW, Adams PD, Winn MD, Storoni LC, Read RJ. Phaser crystallographic software. J Appl Crystallogr. 2007;40(4):658–74. doi:10.1107/S0021889807021206.
   PubMed Web of Science ®Google Scholar
• Murshudov GN, Skubák P, Lebedev AA, Pannu NS, Steiner RA, Nicholls RA, Winn MD, Long F, Vagin AA. REFMAC5 for the refinement of macromolecular crystal structures. Acta Crystallogr D Biol Crystallogr. 2011;67(4):355–67. doi:10.1107/S0907444911001314.
   PubMedGoogle Scholar
• Emsley P, Lohkamp B, Scott WG, Cowtan K. Features and development of coot. Acta Crystallogr D Biol Crystallogr. 2010;66(4):486–501. doi:10.1107/S0907444910007493.
   PubMedGoogle Scholar
• BUSTER Documentation: Usage. https://www.globalphasing.com/buster/manual/autobuster/manual/autoBUSTER4.html.
   Google Scholar
• Davis IW, Leaver-Fay A, Chen VB, Block JN, Kapral GJ, Wang X, Murray LW, Arendall WB, Snoeyink J, Richardson JS, et al. MolProbity: all-atom contacts and structure validation for proteins and nucleic acids. Nucleic Acids Res. 2007;35(Web Server):W375–83. doi:10.1093/nar/gkm216.
   PubMed Web of Science ®Google Scholar
• Incardona M-F, Bourenkov GP, Levik K, Pieritz RA, Popov AN, Svensson O. EDNA: a framework for plugin-based applications applied to X-ray experiment online data analysis. J Synchrotron Radiat. 2009;16(6):872–79. doi:10.1107/S0909049509036681.
   PubMedGoogle Scholar
• Lu C, Wu C, Ghoreishi D, Chen W, Wang L, Damm W, Ross GA, Dahlgren MK, Russell E, Von Bargen CD, et al. OPLS4: improving force field accuracy on challenging regimes of chemical space. J Chem Theory Comput. 2021;17(7):4291–300. doi:10.1021/acs.jctc.1c00302.
   PubMed Web of Science ®Google Scholar
• Bouwstra R, van Meerten T, Bremer E. CD47‐SIRPα blocking‐based immunotherapy: current and prospective therapeutic strategies. Clin Transl Med. 2022;12(8):e943. doi:10.1002/ctm2.943.
   PubMed Web of Science ®Google Scholar
• van Duijn A, Van der Burg SH, Scheeren FA. CD47/SIRPα axis: bridging innate and adaptive immunity. J Immunother Cancer. 2022;10(7):e004589. doi:10.1136/jitc-2022-004589.
   PubMed Web of Science ®Google Scholar
• Logtenberg MEW, Scheeren FA, Schumacher TN. The CD47-SIRPα immune checkpoint. Immunity. 2020;52(5):742–52. doi:10.1016/j.immuni.2020.04.011.
   PubMed Web of Science ®Google Scholar
• Herbst RS, Soria J-C, Kowanetz M, Fine GD, Hamid O, Gordon MS, Sosman JA, McDermott DF, Powderly JD, Gettinger SN, et al. Predictive correlates of response to the anti-PD-L1 antibody MPDL3280A in cancer patients. Nature. 2014;515(7528):563–67. doi:10.1038/nature14011.
   PubMed Web of Science ®Google Scholar
• Hatherley D, Graham SC, Turner J, Harlos K, Stuart DI, Barclay AN. Paired receptor specificity explained by structures of signal regulatory proteins alone and complexed with CD47. Mol Cell. 2008;31(2):266–77. doi:10.1016/j.molcel.2008.05.026.
   PubMed Web of Science ®Google Scholar
• Winn MD, Ballard CC, Cowtan KD, Dodson EJ, Emsley P, Evans PR, Keegan RM, Krissinel EB, Leslie AGW, McCoy A, et al. Overview of the CCP4 suite and current developments. Acta Crystallogr D Biol Crystallogr. 2011;67(4):235–42. doi:10.1107/S0907444910045749.
   PubMed Web of Science ®Google Scholar
• MacCallum RM, Martin AC, Thornton JM. Antibody-antigen interactions: contact analysis and binding site topography. J Mol Biol. 1996;262(5):732–45. doi:10.1006/jmbi.1996.0548.
   PubMed Web of Science ®Google Scholar
• bioinf.org.uk - Prof. Andrew C.R. Martin’s group at UCL. http://www.bioinf.org.uk/abs/info.html.
   Google Scholar
• Huang B, Bai Z, Ye X, Zhou C, Xie X, Zhong Y, Lin K, Ma L. Structural analysis and binding sites of inhibitors targeting the CD47/SIRPα interaction in anticancer therapy. Comput Struct Biotechnol J. 2021;19:5494–503. doi:10.1016/j.csbj.2021.09.036.
   PubMed Web of Science ®Google Scholar
• Weiskopf K, Jahchan NS, Schnorr PJ, Cristea S, Ring AM, Maute RL, Volkmer AK, Volkmer J-P, Liu J, Lim JS, et al. CD47-blocking immunotherapies stimulate macrophage-mediated destruction of small-cell lung cancer. J Clin Invest. 2016;126(7):2610–20. doi:10.1172/JCI81603.
   PubMed Web of Science ®Google Scholar
• Liu K, Tan S, Chai Y, Chen D, Song H, Zhang CWH, Shi Y, Liu J, Tan W, Lyu J, et al. Structural basis of anti-PD-L1 monoclonal antibody avelumab for tumor therapy. Cell Res. 2017;27(1):151–53. doi:10.1038/cr.2016.102.
   PubMed Web of Science ®Google Scholar
• Tan S, Liu K, Chai Y, Zhang CWH, Gao S, Gao GF, Qi J. Distinct PD-L1 binding characteristics of therapeutic monoclonal antibody durvalumab. Protein Cell. 2018;9(1):135–39. doi:10.1007/s13238-017-0412-8.
   PubMed Web of Science ®Google Scholar
• Zhang F, Qi X, Wang X, Wei D, Wu J, Feng L, Cai H, Wang Y, Zeng N, Xu T, et al. Structural basis of the therapeutic anti-PD-L1 antibody atezolizumab. Oncotarget. 2017;8(52):90215–24. doi:10.18632/oncotarget.21652.
   PubMedGoogle Scholar
• Zak KM, Grudnik P, Magiera K, Dömling A, Dubin G, Holak TA. Structural biology of the immune checkpoint receptor PD-1 and its ligands PD-L1/PD-L2. Struct. 2017;25(8):1163–74. doi:10.1016/j.str.2017.06.011.
   Google Scholar
• Mejias-Gomez O, Madsen AV, Skovgaard K, Pedersen LE, Morth JP, Jenkins TP, Kristensen P, Goletz S. A window into the human immune system: comprehensive characterization of the complexity of antibody complementary-determining regions in functional antibodies. Mabs-austin. 2023;15(1):2268255. doi:10.1080/19420862.2023.2268255.
   PubMed Web of Science ®Google Scholar
• Koide S, Sidhu SS. The importance of being tyrosine: lessons in molecular recognition from minimalist synthetic binding proteins. ACS Chem Biol. 2009;4(5):325–34. doi:10.1021/cb800314v.
   PubMed Web of Science ®Google Scholar
• Fellouse FA, Li B, Compaan DM, Peden AA, Hymowitz SG, Sidhu SS. Molecular recognition by a binary code. J Mol Biol. 2005;348(5):1153–62. doi:10.1016/j.jmb.2005.03.041.
   PubMed Web of Science ®Google Scholar
• Stanfield RL, Wilson IA. Antigen-induced conformational changes in antibodies: a problem for structural prediction and design. Trends Biotechnol. 1994;12(7):275–79. doi:10.1016/0167-7799(94)90139-2.
   PubMed Web of Science ®Google Scholar
• Muyldermans S. Nanobodies: natural single-domain antibodies. Annu Rev Biochem. 2013;82(1):775–97. doi:10.1146/annurev-biochem-063011-092449.
   PubMed Web of Science ®Google Scholar
• Matz H, Munir D, Logue J, Dooley H. The immunoglobulins of cartilaginous fishes. Dev Comp Immunol. 2021;115:103873. doi:10.1016/j.dci.2020.103873.
   PubMed Web of Science ®Google Scholar
• Hellmann MD, Bivi N, Calderon B, Shimizu T, Delafontaine B, Liu ZT, Szpurka AM, Copeland V, Hodi FS, Rottey S, et al. Safety and immunogenicity of LY3415244, a bispecific antibody against TIM-3 and PD-L1, in patients with advanced solid tumors. Clin Cancer Res. 2021;27(10):2773–81. doi:10.1158/1078-0432.CCR-20-3716.
   PubMed Web of Science ®Google Scholar
• Zhou Y, Penny HL, Kroenke MA, Bautista B, Hainline K, Chea LS, Parnes J, Mytych DT. Immunogenicity assessment of bispecific antibody-based immunotherapy in oncology. J Immunother Cancer. 2022;10(4):e004225. doi:10.1136/jitc-2021-004225.
   PubMed Web of Science ®Google Scholar